Long-Term Benefit from Adjuvant Tamoxifen in Luminal A and Luminal B Breast Cancer Patients

被引：0
|
作者：
Dar, Huma
Johansson, Annelie
Nordenskjold, Anna
Perez-Tenorio, Gizeh
Yau, Christina
Benz, Christopher C.
Esserman, Laura J.
Nordenskjold, Bo
Stal, Olle
Fornander, Tommy
Lindstrom, Linda S.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P2-03-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-03-04
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Is adjuvant chemotherapy necessary for Luminal A-like breast cancer?
    Taskaynatan, Halil
    Kucukzeybek, Yuksel
    Alacacioglu, Ahmet
    Yildiz, Yasar
    Salman, Tarik
    Oflazoglu, Utku
    Varol, Umut
    Kucukzeybek, Betul Bolat
    Atahan, Murat Kemal
    Tarhan, Mustafa Oktay
    JOURNAL OF BUON, 2018, 23 (04): : 877 - 882
  • [42] RANK expression predicts long term outcome in early luminal breast cancer
    Kassem, L.
    Clezardin, P.
    Treilleux, I.
    ANNALS OF ONCOLOGY, 2018, 29
  • [43] Tailoring Adjuvant Treatments for the Individual Patient with Luminal Breast Cancer
    Munzone, Elisabetta
    Curigliano, Giuseppe
    Colleoni, Marco
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2013, 27 (04) : 703 - +
  • [44] Predicting relapse in estrogen receptor (ER) positive breast cancer (luminal) subgroups treated with adjuvant tamoxifen.
    Loi, SM
    Desmedt, C
    Haibe-Kains, B
    Lallemand, F
    Gillett, C
    Tutt, A
    Ryder, K
    Ellis, P
    Harris, P
    Smeds, J
    Bergh, J
    Cardoso, F
    Piccart, MJ
    Sotiriou, C
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S129 - S130
  • [45] High UTX expression is associated with tamoxifen resistance in luminal A breast cancer
    Kim, Dong-Hoon
    Min, Kyueng-Whan
    Chae, Seoung Wan
    Do, Sung-Im
    Oh, Young-Ha
    Son, Byoung Kwan
    MODERN PATHOLOGY, 2019, 32
  • [46] High UTX expression is associated with tamoxifen resistance in luminal A breast cancer
    Kim, Dong-Hoon
    Min, Kyueng-Whan
    Chae, Seoung Wan
    Do, Sung-Im
    Oh, Young-Ha
    Son, Byoung Kwan
    LABORATORY INVESTIGATION, 2019, 99
  • [47] Vandetanib increases the efficacy of tamoxifen in a preclinical luminal breast cancer model
    Spanheimer, Philip
    Park, Jung M.
    Askeland, Ryan W.
    Cyr, Anthony R.
    Woodfield, George W.
    Weigel, Ronald J.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2013, 217 (03) : S127 - S127
  • [48] Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study
    Diessner, Joachim
    Wischnewsky, Manfred
    Blettner, Maria
    Haeusler, Sebastian
    Janni, Wolfgang
    Kreienberg, Rolf
    Stein, Roland
    Stueber, Tanja
    Schwentner, Lukas
    Bartmann, Catharina
    Woeckel, Achim
    PLOS ONE, 2016, 11 (12):
  • [49] Adjuvant chemotherapy for elderly women with breast cancer: immediate benefit and long-term risk
    Aapro, M. S.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 72 : S9 - S10
  • [50] LONG-TERM EFFECTS OF ADJUVANT TAMOXIFEN AND OR RADIOTHERAPY - THE SOUTH SWEDEN BREAST-CANCER TRIAL
    RYDEN, S
    FERNO, M
    MOLLER, T
    ASPEGREN, K
    BERGLJUNG, L
    KILLANDER, D
    LANDBERG, T
    ACTA ONCOLOGICA, 1992, 31 (02) : 271 - 274
12345